<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">CardioSomatics</journal-id><journal-title-group><journal-title xml:lang="en">CardioSomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>CardioСоматика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2221-7185</issn><issn publication-format="electronic">2658-5707</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">685972</article-id><article-id pub-id-type="doi">10.17816/CS685972</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">«Associations of triglycerides with other parameters of cardiometabolic syndrome in patients with hypertriglyceridemia.»</article-title><trans-title-group xml:lang="ru"><trans-title>«Ассоциации триглицеридов с другими параметрами кардиометаболического синдрома у пациентов с гипертриглицеридемией».</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8620-5370</contrib-id><contrib-id contrib-id-type="researcherid">rid64612</contrib-id><contrib-id contrib-id-type="spin">9074-1605</contrib-id><name-alternatives><name xml:lang="en"><surname>Shomin</surname><given-names>Aleksandr V.</given-names></name><name xml:lang="ru"><surname>Шомин</surname><given-names>Александр Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assistant of the Department of Hospital Therapy at St. Petersburg State University, cardiologist at the My Medical Center Group of Clinics, St. Petersburg.</p></bio><bio xml:lang="ru"><p>ассистент кафедры госпитальной терапии СПБГУ, врач-кардиолог ООО группы клиник «Мой Медицинский Центр», Санкт-Петербург.</p></bio><email>survivorstar9@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4239-9550</contrib-id><contrib-id contrib-id-type="scopus">57218214175</contrib-id><contrib-id contrib-id-type="researcherid">ACS-3089-2022</contrib-id><contrib-id contrib-id-type="spin">6436-7552</contrib-id><name-alternatives><name xml:lang="en"><surname>Serezhina</surname><given-names>Elena K.</given-names></name><name xml:lang="ru"><surname>Сережина</surname><given-names>Елена Константиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>candidate of medical sciences, Assistant of the Department of Hospital Therapy at St. Petersburg State University, cardiologist at the My Medical Center Group of Clinics, St. Petersburg.</p></bio><bio xml:lang="ru"><p>кандидат медицинский наук, ассистент кафедры госпитальной терапии СПБГУ, врач-кардиолог ООО группы клиник «Мой Медицинский Центр», Санкт-Петербург.</p></bio><email>zlotnikova.elena.konst@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6115-7923</contrib-id><contrib-id contrib-id-type="spin">4790-3880</contrib-id><name-alternatives><name xml:lang="en"><surname>Obrezan</surname><given-names>Andrey G.</given-names></name><name xml:lang="ru"><surname>Обрезан</surname><given-names>Андрей Григорьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Doctor of Medical Sciences, Professor and Head of the Department of Hospital Therapy at St. Petersburg State University, cardiologist at the My Medical Center Group of Clinics, St. Petersburg.</p></bio><bio xml:lang="ru"><p>доктор медицинский наук, профессор и заведующий кафедрой госпитальной терапии СПБГУ, врач-кардиолог ООО группы клиник «Мой Медицинский Центр», Санкт-Петербург.</p></bio><email>obrezan1@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">LLC Group of Clinics "My Medical Center", Saint Petersburg</institution></aff><aff><institution xml:lang="ru">ООО группа клиник «Мой Медицинский Центр», Санкт-Петербург</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State University", Russian Federation.</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Санкт-Петербургский государственный университет», Российская Федерация.</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-07-22" publication-format="electronic"><day>22</day><month>07</month><year>2026</year></pub-date><volume>17</volume><issue>1</issue><issue-title xml:lang="ru"/><history><date date-type="received" iso-8601-date="2025-07-11"><day>11</day><month>07</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2026-03-17"><day>17</day><month>03</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; , Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; , ООО "Эко-Вектор"</copyright-statement><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2029-07-14"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://cardiosomatics.ru/2221-7185/article/view/685972">https://cardiosomatics.ru/2221-7185/article/view/685972</self-uri><abstract xml:lang="en"><p>Relevance. Triglycerides are one of the key components of lipid metabolism, which play an important role in the development of cardiometabolic syndrome, which is a set of risk factors for cardiovascular diseases. Identification of correlations of triglyceride levels with other parameters of cardiometabolic syndrome has great scientific and practical value.</p> <p>Objective. Study of correlations of triglycerides with other parameters of cardiometabolic syndrome among patients with hypertriglyceridemia.</p> <p>Materials and methods. The study was retrospective, the sample included 693 patients aged 18 to 90 years with a cardiological profile with hypertriglyceridemia. Spearman's rank correlation coefficient was used to determine the correlation of parameters, the strength of the relationship was determined according to Chaddock.</p> <p>Results. The following correlations of triglycerides with cardiometabolic syndrome parameters were found among patients with hypertriglyceridemia: weight (r = 0.21, p &lt; 0.001), body mass index (r = 0.23, p &lt; 0.001), visceral fat index (r = 0.784, p &lt; 0.001), waist circumference (r = 0.111, p = 0.045), METS-IR index (r = 0.358, p &lt; 0.001), plasma atherogenicity index (r = 0.815, p &lt; 0.001), glucose (r = 0.142, p = 0.001), HOMA-IR index (r = 0.20, p = 0.004), fasting blood insulin (r = 0.471, p &lt; 0.001), total cholesterol (r = 0.265, p &lt; 0.001), high-density lipoproteins (r = -0.266, p &lt; 0.001), very low-density lipoproteins (r = 0.965, p &lt; 0.001).</p> <p>Conclusions. Triglycerides play a central role in the pathogenesis of cardiometabolic syndrome, interacting with other components of this condition through complex mechanisms of regulation of lipid and carbohydrate metabolism. The presence of elevated serum triglyceride levels is associated with abdominal obesity, type 2 diabetes mellitus, and arterial hypertension. In the presence of hypertriglyceridemia, a significant increase in blood pressure, high levels of total cholesterol, and very low-density lipoproteins are observed. </p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность. </bold> Триглицериды — одни из ключевых компонентов липидного обмена, которые играют важную роль в развитии кардиометаболического синдрома, представляющего собой совокупность факторов риска сердечно-сосудистых заболеваний. Выявление корреляций уровня триглицеридов с другими параметрами кардиометаболического синдрома имеет большую научную и практическую ценность.</p> <p><bold>Цель. </bold>Изучение корреляций триглицеридов с другими параметрами кардиометаболического синдрома среди пациентов с гипертриглицеридемией.</p> <p><bold>Материалы и методы. </bold>Исследование имело ретроспективный характер, выборка включала 693 пациента в возрасте от 18 до 90 лет кардиологического профиля с гипертриглицеридемией. Коэффициент ранговой корреляции Спирмена применялся для определения корреляции параметров, Сила связи определялась по Чеддоку.</p> <p><bold>Результаты. </bold> Были выявлены следующие корреляции триглицеридов с параметрами кардиометаболического синдрома среди пациентов с гипертриглицеридемией: вес (r = 0,21, p<bold> </bold>&lt; 0,001), индекс массы тела (r = 0,23, p<bold> </bold>&lt; 0,001), индекс висцерального жира (r= 0,784, p &lt; 0,001), окружность талии (r = 0,111, p = 0,045), индекс METS—IR (r = 0,358, p<bold> </bold>&lt; 0,001), индекс атерогенности плазмы (r = 0,815, p<bold> </bold>&lt; 0,001), глюкоза (r = 0,142, p=0,001), индекс HOMA-IR (r = 0,20, p<bold> </bold>= 0,004), инсулин крови натощак (r = 0,471, p<bold> </bold>&lt; 0,001), общий холестерин (r = 0,265, p<bold> </bold>&lt; 0,001), липопротеины высокой плотности (r = -0,266, p<bold> </bold>&lt; 0,001), липопротеины очень низкой плотности (r = 0,965, p<bold> </bold>&lt; 0,001), остаточный холестерин (r = 0,511, p<bold> </bold>&lt; 0,001), мочевая кислота (r = 0,189, p<bold> </bold>&lt; 0,001).</p> <p><bold>Выводы. </bold>Триглицериды играют центральную роль в патогенезе кардиометаболического синдрома, взаимодействуя с другими компонентами этого состояния через сложные механизмы регуляции липидного и углеводного обменов. Наличие повышенных уровней триглицеридов сыворотки крови ассоциируется с абдоминальным ожирением, сахарным диабетом 2 типа, артериальной гипертензией. При наличии гипертриглицеридемии наблюдается значимое повышение уровня артериального давления, высокие уровни общего холестерина, липопротеинов очень низкой плотности. Триглицериды связаны со всеми компонентами кардиометаболического синдрома, наиболее вероятно, за счет феномена инсулинорезистентности, что требуется учитывать в комплексной курации данных когорт пациентов. Необходимы дальнейшие исследования в данной области знаний.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hypertriglyceridemia</kwd><kwd>dyslipidemia</kwd><kwd>triglycerides</kwd><kwd>lipids</kwd><kwd>lipidology</kwd><kwd>cholesterol</kwd><kwd>atherosclerosis</kwd><kwd>cardiovascular diseases</kwd><kwd>metabolic syndrome</kwd><kwd>insulin resistance.</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гипертриглицеридемия</kwd><kwd>дислипидемия</kwd><kwd>триглицериды</kwd><kwd>липиды</kwd><kwd>липидология</kwd><kwd>холестерин</kwd><kwd>атеросклероз</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>метаболический синдром</kwd><kwd>инсулинорезистентность.</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kanodia, A.K., Noland, D. (2020). Cardiometabolic Syndrome. In: Noland, D., Drisko, J., Wagner, L. (eds) Integrative and Functional Medical Nutrition Therapy. Humana, Cham. https://doi.org/10.1007/978-3-030-30730-1_46.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Kytikova O.Y., Antonyuk M.V., Kantur T.A., Novgorodtseva T.P., Denisenko Y.K. Prevalence and biomarkers in metabolic syndrome. Obesity and metabolism. 2021;18(3):302-312. (In Russ.) https://doi.org/10.14341/omet12704.</mixed-citation><mixed-citation xml:lang="ru">Кытикова О.Ю., Антонюк М.В., Кантур Т.А., Новгородцева Т.П., Денисенко Ю.К. Распространенность и биомаркеры метаболического синдрома. Ожирение и метаболизм. 2021;18(3):302-312. https://doi.org/10.14341/omet12704.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the Metabolic Syndrome. Circulation. 2005;112(17):35-52. https://doi.org/10.1161/CIRCULATIONAHA.105.169405.</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Recommendations for the management of patients with metabolic syndrome. Clinical recommendations. - M.: 2013. - 43 p.</mixed-citation><mixed-citation xml:lang="ru">Рекомендации по ведению больных с метаболическим синдромом. Клинические рекомендации. - М.: 2013. - 43 с.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Geto, Z., Challa, F., Lejisa, T. et al. Cardiometabolic syndrome and associated factors among Ethiopian public servants, Addis Ababa, Ethiopia. Sci Rep 11, 20635 (2021). https://doi.org/10.1038/s41598-021-99913-6.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Chen W, Chen Y. Cardiometabolic Syndrome and Vascular Calcification. Cardiometab Syndr J. 2022 Mar;2(1):1-21. https://doi.org/10.51789/cmsj.2022.2.e2.</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Arutyunov G.P., Boytsov S.A., Voevoda M.I., Drapkina O.M., Kukharchuk V.V., Martynov A.I., Shestakova M.V., Gurevich V.S., Sergienko I.V., Alieva A.S., Akhmedzhanov N.M., Bubnova M.G., Galyavich A.S., Gordeev I.G., Yezhov M.V., Karpov Yu.A., Konstantinov V.O., Nedogoda S.V., Nifontov E.M., Orlova Y.A., Panov A.V., Saiganov S.A., Skibitsky V.V., Tarlovskaya E.I., Urazgildeeva S.A., Khalimov Yu.Sh. Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion. Russian Journal of Cardiology. 2019;(9):44-51. https://doi.org/10.15829/1560-4071-2019-9-44-51.</mixed-citation><mixed-citation xml:lang="ru">Арутюнов Г. П., Бойцов С. А., Воевода М. И. и др. Коррекция гипертриглицеридемии с целью снижения остаточного риска при заболеваниях, вызванных атеросклерозом. Заключение Совета экспертов. Российский кардиологический журнал. 2019;(9):44-51. https://doi.org/10.15829/1560-4071-2019-9-44-51.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R., Riccardi G., Richter D.J., Sabatine M.S., Taskinen M., Tokgozoglu L., Wiklund O. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk. Russian Journal of Cardiology. 2020;25(5):3826. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3826.</mixed-citation><mixed-citation xml:lang="ru">Mach F., Baigent C., Catapano A.L., Koskinas K.С., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.А., Graham I.М., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R., Riccardi G., Richter D.J., Sabatine M.S., Taskinen M., Tokgozoglu L., Wiklund O. 2019 Рекомендации ESC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска. Российский кардиологический журнал. 2020;25(5):3826. https://doi.org/10.15829/1560-4071-2020-3826.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><mixed-citation>Cho Y, Lee S, Jee SH, Kim J.  Hypertriglyceridemia is a Major Factor Associated With Elevated Levels of Small Dense LDL Cholesterol in Patients With Metabolic Syndrome.  Ann Lab Med 2015;35:586-594.  https://doi.org/10.3343/alm.2015.35.6.586.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zhaoping Li, Max L. Deng, Chi-Hong Tseng, et al. Hypertriglyceridemia Is a Practical Biomarker of Metabolic Syndrome in Individuals with Abdominal Obesity. Metabolic Syndrome and Related Disorders. 2013. Vol. 11, No. 2. https://doi.org/10.1089/met.2012.0090.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>De Cuevillas, B., Alvarez-Alvarez, I., Riezu-Boj, J.I. et al. The hypertriglyceridemic-waist phenotype as a valuable and integrative mirror of metabolic syndrome traits. Sci Rep 11, 21859 (2021). https://doi.org/10.1038/s41598-021-01343-x.</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Veselovskaya N.G., Chumakova G.A., Shenkova N.N., Osipova E.S., Gritsenko O.V. RISK ASSESSMENT MODEL FOR CORONARY ATHEROSCLEROSIS IN PATIENTS WITH VISCERAL OBESITY. Russian Journal of Cardiology. 2015;(4):49-54. (In Russ.) https://doi.org/10.15829/1560-4071-2015-4-49-54.</mixed-citation><mixed-citation xml:lang="ru">Веселовская Н. Г., Чумакова Г. А., Шенкова Н. Н. и др. Модель прогнозирования риска коронарного атеросклероза у пациентов с висцеральным ожирением. Российский кардиологический журнал. 2015;(4):49-54. https://doi.org/10.15829/1560-4071-2015-4-49-54.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Marco Gelpi, Shoaib Afzal, Jens Lundgren, Andreas Ronit, Ashley Roen, Amanda Mocroft, Jan Gerstoft, Anne-Mette Lebech, Birgitte Lindegaard, Klaus Fuglsang Kofoed, Børge G Nordestgaard, Susanne Dam Nielsen, Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study, Clinical Infectious Diseases, Volume 67, Issue 4, 15 August 2018, Pages 579–586, https://doi.org/10.1093/cid/ciy146.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Lee, H., Lee, H., Cho, J. et al. Overall and abdominal adiposity and hypertriglyceridemia among Korean adults: the Korea National Health and Nutrition Examination Survey 2007–2008. Eur J Clin Nutr 67, 83–90 (2013). https://doi.org/10.1038/ejcn.2012.181.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015;36:131–147. doi: 10.1210/er.2014-1062.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ormazabal, V., Nair, S., Elfeky, O. et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 17, 122 (2018). https://doi.org/10.1186/s12933-018-0762-4.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ma, M., Liu, H., Yu, J. et al. Triglyceride is independently correlated with insulin resistance and islet beta cell function: a study in population with different glucose and lipid metabolism states. Lipids Health Dis 19, 121 (2020). https://doi.org/10.1186/s12944-020-01303-w.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Rinkūnienė, E., Dženkevičiūtė, V., Petrulionienė, Ž. et al. Hypertriglyceridemia impact on arterial parameters in patients with metabolic syndrome. BMC Cardiovasc Disord 21, 393 (2021). https://doi.org/10.1186/s12872-021-02202-3.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Lian Yong Liu, Qing Gu, Xue Hu, Jie Fan. Potential Mediators of Causal Associations of Circulating Triglycerides With Blood Pressure: Evidence From Genetic and Observational Data. Hypertension. Volume 79, Number 11. https://doi.org/10.1161/HYPERTENSIONAHA.122.19510.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Welty, F.K. How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?. Curr Cardiol Rep 15, 400 (2013). https://doi.org/10.1007/s11886-013-0400-4.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Christie M. Ballantyne, Anders G. Olsson, Thomas J. Cook et al. Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S. Circulation. Volume 104, Number 25. https://doi.org/10.1161/hc5001.100624.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Richard Rarison Cavalcante Meneses et al. Hypertriglyceridemia promotes dysfunctions in high-density lipoprotein increasing the cardiovascular risk.  Braz. J. Pharm. Sci. 58. 2022. https://doi.org/10.1590/s2175-97902022e20488.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Wieczorek E, Ćwiklińska A, Kuchta A, Kortas-Stempak B, Gliwińska A, Jankowski M. Decreased Efficiency of Very-Low-Density Lipoprotein Lipolysis Is Linked to Both Hypertriglyceridemia and Hypercholesterolemia, but It Can Be Counteracted by High-Density Lipoprotein. Nutrients. 2021; 13(4):1224. https://doi.org/10.3390/nu13041224.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Cathy J Sun, Christopher McCudden, Diane Brisson, Julie Shaw, Daniel Gaudet, Teik C Ooi, Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia, Journal of the Endocrine Society, Volume 4, Issue 1, January 2020, bvz010, https://doi.org/10.1210/jendso/bvz010.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Antonio J Vallejo-Vaz, Lawrence A Leiter, Stefano Del Prato, Marja-Riitta Taskinen, Dirk Müller-Wieland, Maja Bujas-Bobanovic, Alexia Letierce, Jonas Mandel, Rita Samuel, Kausik K Ray, Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab, European Journal of Preventive Cardiology, Volume 27, Issue 15, 1 October 2020, Pages 1663–1674, https://doi.org/10.1177/2047487320905185.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Zhao, Y., Zhuang, Z., Li, Y. et al. Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity. Nat Commun 15, 2451 (2024). https://doi.org/10.1038/s41467-024-46686-x.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Eirik Aaseth, Sigrun Halvorsen, Ragnhild Helseth, Jørgen Gravning, Remnant cholesterol, plasma triglycerides, and risk of cardiovascular disease events in young adults: a prospective cohort study, European Journal of Preventive Cardiology, 2025;, zwaf104, https://doi.org/10.1093/eurjpc/zwaf104.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Fang, Y., Mei, W., Wang, C. et al. Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China. BMC Endocr Disord 24, 2 (2024). https://doi.org/10.1186/s12902-023-01528-7.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Hou, Yl., Yang, Xl., Wang, Cx. et al. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis 18, 81 (2019). https://doi.org/10.1186/s12944-019-1031-6.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Mo-Yao Tan, Chao-Yue Mo, Fang Li et al. The association between serum uric acid and hypertriglyceridemia: evidence from the national health and nutrition examination survey (2007–2018). Front. Endocrinol., 18 July 2023. Volume 14 - 2023. https://doi.org/10.3389/fendo.2023.1215521.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Zhang, Y., Zhang, M., Yu, X. et al. Association of hypertension and hypertriglyceridemia on incident hyperuricemia: an 8-year prospective cohort study. J Transl Med 18, 409 (2020). https://doi.org/10.1186/s12967-020-02590-8.</mixed-citation></ref></ref-list></back></article>
